INDVIndivior Pharmaceuticals, Inc.
Price
+59%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality mixed, a flag to check, undemanding price, growing in the filings, the market undecided.
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $343M in Q2 2026 (quarter ended Jun 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 86% and net income of $122M (36% of revenue). For the full year FY2025, revenue was $1.24B (+4.3% year on year) and net income $210M. Its largest product in Q2 2026 was Sublocade at $238M, 79% of the disclosed total, well ahead of Sublingual And Other at 19%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 6, 2026As previously reported, on August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (the “Indivior”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”) and Artemis Merger Sub Inc., a Delaware corporation and a …Other event · Form 8-K
- Sep 15, 2026On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement")Material agreement terminated · Form 8-K
- Aug 3, 2026Merger of Equals to Create a.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $300.0MThe company’s own SEC segment disclosure.
- Sublocade$238.0M79%
- Sublingual And Other$57.0M19%
- Perseris$5.0M2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #1 of 41 by RyuScore